AOD 9604

AOD 9604 was tested properly, and that is the problem

AOD-9604 is a modified fragment of growth hormone, developed specifically for fat loss without growth hormone’s other effects. This section holds 4 lines from £62 to £93.

Unusually for anything in the peptides range, it went through proper human clinical trials for obesity. That is normally the strongest thing you can say about a compound. Here it is the weakest, because of how the trials turned out.

What the trials found

The development programme progressed to substantial human studies in obese patients. In the pivotal work, AOD-9604 did not produce weight loss significantly greater than placebo at the endpoints assessed, and development for obesity was discontinued.

This matters more than an absence of evidence would. Most compounds sold here are untested — the honest position is “unknown”. AOD-9604 was tested at scale in the population it was designed for and did not deliver.

Why it is still sold

It has an excellent safety profile — that much the trials did establish, and it is the reason it was later explored for other indications such as cartilage and joint conditions. It is well tolerated and does not affect blood glucose or IGF-1 the way full growth hormone does.

Safe and ineffective is a specific combination. It is genuinely low-risk, and the fat-loss claim it is sold on is the claim its own trials failed to support.

Against the fragment it is confused with

AOD-9604 is closely related to HGH fragment 176-191, and the two are frequently conflated. The trial history described here is the most informative human evidence available for either, which is why it is worth knowing when considering the fragment as well.

Anyone whose actual goal is fat loss should compare against the fat burners range, where compounds with demonstrated effects exist.

What the trial history is genuinely useful for

It is a rare opportunity to see what happens when something from this catalogue gets tested properly. Most compounds here are sold on mechanism, animal data or user report, and the honest answer about them is that nobody knows. AOD-9604 is the case where somebody found out.

That makes it a useful reference point when weighing anything else sold on a plausible mechanism, including the growth hormone secretagogues in the growth hormone range. A convincing mechanism and a real effect are different things, and the gap between them is where most of this market lives.

Handling

Lyophilised on arrival, reconstituted with bacteriostatic water, refrigerated once mixed and used within a few weeks.

Where the name comes from

AOD stands for anti-obesity drug, which tells you exactly what it was built for and makes the trial outcome more pointed than it would otherwise be. The 9604 is a development code.

Frequently asked questions

Does AOD-9604 work for fat loss?
Its human obesity trials did not show a significant advantage over placebo, and development was discontinued.

Is it safe?
The trials established a good tolerability profile. It does not affect blood glucose or IGF-1 as growth hormone does.

Why is it still sold then?
It is well tolerated and inexpensive, and the trial result is not widely known.

How does it differ from HGH fragment 176-191?
Closely related, frequently conflated. AOD-9604’s trial history is the best human data on either.

Does it need PCT?
No. It does not act on the androgen axis.